Outpatient Antibiotic Stewardship: A Growing Frontier-Combining Myxovirus Resistance Protein A With Other Biomarkers to Improve Antibiotic Use

Patrick Joseph, Eliot Godofsky, Patrick Joseph, Eliot Godofsky

Abstract

Background: The majority of oral antibiotics are prescribed in outpatient primary and urgent care clinics for acute respiratory infections. Effective antibiotic stewardship must include proper prescribing for outpatients as well as for those in a hospital or long-term care facility.

Methods: Major databases, including MEDLINE and the Cochrane Library, were searched for prospective human clinical studies, including children and/or adults published between January 1966 and November 2017 that evaluated Myxovirus resistance protein A (MxA) as a biomarker for diagnosing viral infections as well as both C-reactive protein (CRP) and procalcitonin (PCT) as potential biomarkers for identifying and differentiating true bacterial upper respiratory infection (URI) from colonization.

Results: Ten prospective human studies, totaling 1683 patients, were identified that evaluated MxA as a viral biomarker in children and/or adults. Both systematic review articles, meta-analyses, and randomized controlled clinical trials that examined CRP and/or PCT as a biomarker for identifying clinically significant bacterial infections and supporting antibiotic stewardship were identified.

Conclusions: Quick and accurate differentiation between a viral and bacterial respiratory infection is critical to effectively combat antibiotic misuse. MxA expression in peripheral blood is a highly specific marker for viral infection. Combining MxA with other inflammatory biomarkers to test for respiratory infections offers enhanced sensitivity and specificity, forming an excellent tool for antibiotic stewardship in the outpatient setting.

Keywords: C-reactive protein (CRP); FebriDx; diagnostic; myxovirus resistance protein A (MxA); point of care (POC); procalcitonin (PCT); upper respiratory infection (URI).

References

    1. Harris AM, Hicks LA, Qaseem A. Appropriate antibiotic use for acute respiratory tract infection in adults. Ann Intern Med 2016; 165:674.
    1. Bisno AL. Acute pharyngitis. N Engl J Med 2001; 344:205–11.
    1. Ivaska L, Niemelä J, Lempainen J et al. . Aetiology of febrile pharyngitis in children: potential of myxovirus resistance protein A (MxA) as a biomarker of viral infection. J Infect 2017; 74:385–92.
    1. Neuner JM, Hamel MB, Phillips RS et al. . Diagnosis and management of adults with pharyngitis. A cost-effectiveness analysis. Ann Intern Med 2003; 139:113–22.
    1. Cooper RJ, Hoffman JR, Bartlett JG et al. ; Centers for Disease Control and Prevention Principles of appropriate antibiotic use for acute pharyngitis in adults: background. Ann Emerg Med 2001; 37:711–9.
    1. Steinman MA, Gonzales R, Linder JA, Landefeld CS. Changing use of antibiotics in community-based outpatient practice, 1991-1999. Ann Intern Med 2003; 138:525–33.
    1. Sambursky R, Shapiro N. Evaluation of a combined MxA and CRP point-of-care immunoassay to identify viral and/or bacterial immune response in patients with acute febrile respiratory infection. Eur Clin Respir J 2015; 2:28245.
    1. Self WH, Rosen J, Sharp SC et al. . Diagnostic accuracy of FebriDx: a rapid test to detect immune responses to viral and bacterial upper respiratory infections. J Clin Med 2017; 6:E94.
    1. Davidson M. FebriDx point-of-care testing to guide antibiotic therapy for acute respiratory tract infection in UK primary care: a retrospective outcome analysis. J Infect Dis Preve Med. 2017; 5:165.
    1. Felsenstein S, Faddoul D, Sposto R et al. . Molecular and clinical diagnosis of group A streptococcal pharyngitis in children. J Clin Microbiol 2014; 52:3884–9.
    1. Hoover SE, Kawada J, Wilson W, Cohen JI. Oropharyngeal shedding of Epstein-Barr virus in the absence of circulating B cells. J Infect Dis 2008; 198:318–23.
    1. Mertz GJ. Asymptomatic shedding of herpes simplex virus 1 and 2: implications for prevention of transmission. J Infect Dis 2008; 198:1098–100.
    1. Taylor GH. Cytomegalovirus. Am Fam Physician 2003; 67:519–24.
    1. Gerber MA, Baltimore RS, Eaton CB et al. . Prevention of rheumatic fever and diagnosis and treatment of acute Streptococcal pharyngitis: a scientific statement from the American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee of the Council on Cardiovascular Disease in the Young, the Interdisciplinary Council on Functional Genomics and Translational Biology, and the Interdisciplinary Council on Quality of Care and Outcomes Research: endorsed by the American Academy of Pediatrics. Circulation 2009; 119:1541–51.
    1. Kaplan EL, Top FH Jr, Dudding BA, Wannamaker LW. Diagnosis of streptococcal pharyngitis: differentiation of active infection from the carrier state in the symptomatic child. J Infect Dis 1971; 123:490–501.
    1. Gerber MA, Randolph MF, Chanatry J et al. . Antigen detection test for streptococcal pharyngitis: evaluation of sensitivity with respect to true infections. J Pediatr 1986; 108:654–8.
    1. Kaplan EL, Wannamaker LW. C-reactive protein in streptococcal pharyngitis. Pediatrics 1977; 60:28–32.
    1. Nussinovitch M, Finkelstein Y, Amir J, Varsano I. Group A beta-hemolytic streptococcal pharyngitis in preschool children aged 3 months to 5 years. Clin Pediatr (Phila) 1999; 38:357–60.
    1. Wannamaker LW, Ayoub EM. Antibody titers in acute rheumatic fever. Circulation 1960; 21:598–614.
    1. Hanson LA, Jodal U, Sabel KG, Wadsworth C. The diagnostic value of C-reactive protein. Pediatr Infect Dis 1983; 2:87–9.
    1. Shulman ST, Gerber MA, Tanz RR, Markowitz M. Streptococcal pharyngitis: the case for penicillin therapy. Pediatr Infect Dis J 1994; 13:1–7.
    1. Valkenburg HA, Haverkorn MJ, Goslings WR et al. . Streptococcal pharyngitis in the general population. II. The attack rate of rheumatic fever and acute glomerulonephritis in patients. J Infect Dis 1971; 124:348–58.
    1. Gerber MA, Randolph MF, Mayo DR. The group A streptococcal carrier state. A reexamination. Am J Dis Child 1988; 142:562–5.
    1. Engelmann I, Dubos F, Lobert PE et al. . Diagnosis of viral infections using myxovirus resistance protein A (MxA). Pediatrics 2015; 135:e985–93.
    1. Kawamura M, Kusano A, Furuya A et al. . New sandwich-type enzyme-linked immunosorbent assay for human MxA protein in a whole blood using monoclonal antibodies against GTP-binding domain for recognition of viral infection. J Clin Lab Anal 2012; 26:174–83.
    1. Nakabayashi M, Adachi Y, Itazawa T et al. . MxA-based recognition of viral illness in febrile children by a whole blood assay. Pediatr Res 2006; 60:770–4.
    1. Forster J, Schweizer M, Schumacher RF et al. . MxA protein in infants and children with respiratory tract infection. Acta Paediatr 1996; 85:163–7.
    1. Chieux V, Hober D, Chehadeh W et al. . MxA protein in capillary blood of children with viral infections. J Med Virol 1999; 59:547–51.
    1. Chieux V, Hober D, Harvey J et al. . The MxA protein levels in whole blood lysates of patients with various viral infections. J Virol Methods 1998; 70:183–91.
    1. Halminen M, Ilonen J, Julkunen I et al. . Expression of MxA protein in blood lymphocytes discriminates between viral and bacterial infections in febrile children. Pediatr Res 1997; 41:647–50.
    1. Sen GC, Ransohoff RM. Interferon-induced antiviral actions and their regulation. Adv Virus Res 1993; 42:57–102.
    1. Ronni T, Melén K, Malygin A, Julkunen I. Control of IFN-inducible MxA gene expression in human cells. J Immunol 1993; 150:1715–26.
    1. van der Does Y, Tjikhoeri A, Ramakers C et al. . TRAIL and IP-10 as biomarkers of viral infections in the emergency department. J Infect 2016; 72:761–3.
    1. Ebell MH, McKay B, Guilbault R, Ermias Y. Diagnosis of acute rhinosinusitis in primary care: a systematic review of test accuracy. Br J Gen Pract 2016; 66:e612–32.
    1. Calviño O, Llor C, Gómez F et al. . Association between C-reactive protein rapid test and group A streptococcus infection in acute pharyngitis. J Am Board Fam Med 2014; 27:424–6.
    1. Putto A, Ruuskanen O, Meurman O et al. . C reactive protein in the evaluation of febrile illness. Arch Dis Child 1986; 61:24–9.
    1. Simon L, Gauvin F, Amre DK et al. . Serum procalcitonin and C-reactive protein levels as markers of bacterial infection: a systematic review and meta-analysis. Clin Infect Dis 2004; 39:206–17.
    1. Sarov I, Shainkin-Kestenbaum R, Zimlichman S et al. . Serum amyloid A levels in patients with infections due to cytomegalovirus, varicella-zoster virus, and herpes simplex virus. J Infect Dis 1982; 146:443.
    1. Dandona P, Nix D, Wilson MF et al. . Procalcitonin increase after endotoxin injection in normal subjects. J Clin Endocrinol Metab 1994; 79:1605–8.
    1. Schuetz P, Wirz Y, Sager R et al. . Procalcitonin to initiate or discontinue antibiotics in acute respiratory tract infections. Cochrane Database Syst Rev 2017; 10:CD007498.
    1. Gilbert DN. Use of plasma procalcitonin levels as an adjunct to clinical microbiology. J Clin Microbiol 2010; 48:2325–9.
    1. Christensen AM, Thomsen MK, Ovesen T, Klug TE. Are procalcitonin or other infection markers useful in the detection of group A streptococcal acute tonsillitis?Scand J Infect Dis 2014; 46:376–83.
    1. Elsammak M, Hanna H, Ghazal A et al. . Diagnostic value of serum procalcitonin and C-reactive protein in Egyptian children with streptococcal tonsillopharyngitis. Pediatr Infect Dis J 2006; 25:174–6.
    1. Yu Y, Li XX, Jiang LX et al. . Procalcitonin levels in patients with positive blood culture, positive body fluid culture, sepsis, and severe sepsis: a cross-sectional study. Infect Dis (Lond) 2016; 48:63–9.
    1. Meili M, Müller B, Kulkarni P, Schütz P. Management of patients with respiratory infections in primary care: procalcitonin, C-reactive protein or both?Expert Rev Respir Med 2015; 9:587–601.
    1. Branche AR, Walsh EE, Vargas R et al. . Serum procalcitonin measurement and viral testing to guide antibiotic use for respiratory infections in hospitalized adults: a randomized controlled trial. J Infect Dis 2015; 212:1692–700.
    1. Chirouze C, Schuhmacher H, Rabaud C et al. . Low serum procalcitonin level accurately predicts the absence of bacteremia in adult patients with acute fever. Clin Infect Dis 2002; 35:156–61.
    1. Korppi M, Remes S, Heiskanen-Kosma T. Serum procalcitonin concentrations in bacterial pneumonia in children: a negative result in primary healthcare settings. Pediatr Pulmonol 2003; 35:56–61.
    1. Meili M, Kutz A, Briel M et al. . Infection biomarkers in primary care patients with acute respiratory tract infections-comparison of Procalcitonin and C-reactive protein. BMC Pulm Med 2016; 16:43.
    1. Eccles S, Pincus C, Higgins B, Woodhead M; Guideline Development Group Diagnosis and management of community and hospital acquired pneumonia in adults: summary of NICE guidance. BMJ 2014; 349:g6722.
    1. Huang Y, Chen R, Wu T et al. . Association between point-of-care CRP testing and antibiotic prescribing in respiratory tract infections: a systematic review and meta-analysis of primary care studies. Br J Gen Pract 2013; 63:e787–94.
    1. Cooke J, Butler C, Hopstaken R et al. . Narrative review of primary care point-of-care testing (POCT) and antibacterial use in respiratory tract infection (RTI). BMJ Open Respir Res 2015; 2:e000086.
    1. Cals JW, Butler CC, Hopstaken RM et al. . Effect of point of care testing for C reactive protein and training in communication skills on antibiotic use in lower respiratory tract infections: cluster randomised trial. BMJ 2009; 338:b1374.
    1. Steurer J, Held U, Spaar A et al. . A decision aid to rule out pneumonia and reduce unnecessary prescriptions of antibiotics in primary care patients with cough and fever. BMC Med 2011; 9:56.
    1. Andreeva E, Melbye H. Usefulness of C-reactive protein testing in acute cough/respiratory tract infection: an open cluster-randomized clinical trial with C-reactive protein testing in the intervention group. BMC Fam Pract 2014; 15:80.
    1. Llor C, Moragas A, Hernández S et al. . Efficacy of antibiotic therapy for acute exacerbations of mild to moderate chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2012; 186:716–23.
    1. Tang J, Long W, Yan L et al. . Procalcitonin guided antibiotic therapy of acute exacerbations of asthma: a randomized controlled trial. BMC Infect Dis 2013; 13:596.
    1. Christ-Crain M, Jaccard-Stolz D, Bingisser R et al. . Effect of procalcitonin-guided treatment on antibiotic use and outcome in lower respiratory tract infections: cluster-randomised, single-blinded intervention trial. Lancet 2004; 363:600–7.
    1. Christ-Crain M, Stolz D, Bingisser R et al. . Procalcitonin guidance of antibiotic therapy in community-acquired pneumonia: a randomized trial. Am J Respir Crit Care Med 2006; 174:84–93.
    1. Stolz D, Christ-Crain M, Morgenthaler NG et al. . Copeptin, C-reactive protein, and procalcitonin as prognostic biomarkers in acute exacerbation of COPD. Chest 2007; 131:1058–67.
    1. Briel M, Schuetz P, Mueller B et al. . Procalcitonin-guided antibiotic use vs a standard approach for acute respiratory tract infections in primary care. Arch Intern Med 2008; 168:2000–7; discussion 2007–8.
    1. Schuetz P, Christ-Crain M, Müller B. Procalcitonin and other biomarkers to improve assessment and antibiotic stewardship in infections–hope for hype?Swiss Med Wkly 2009; 139:318–26.
    1. Burkhardt O, Ewig S, Haagen U et al. . Procalcitonin guidance and reduction of antibiotic use in acute respiratory tract infection. Eur Respir J 2010; 36:601–7.
    1. Lieberman D, Shvartzman P, Korsonsky I, Lieberman D. Aetiology of respiratory tract infections: clinical assessment versus serological tests. Br J Gen Pract 2001; 51:998–1000.
    1. Long W, Li LJ, Huang GZ et al. . Procalcitonin guidance for reduction of antibiotic use in patients hospitalized with severe acute exacerbations of asthma: a randomized controlled study with 12-month follow-up. Crit Care 2014; 18:471.
    1. Llor C, Bjerrum L, Munck A et al. ; HAPPY AUDIT Investigators Access to point-of-care tests reduces the prescription of antibiotics among antibiotic-requesting subjects with respiratory tract infections. Respir Care 2014; 59:1918–23.
    1. Caliendo AM, Gilbert DN, Ginocchio CC et al. ; Infectious Diseases Society of America (IDSA) Better tests, better care: improved diagnostics for infectious diseases. Clin Infect Dis 2013; 57(Suppl 3):S139–70.
    1. Wiselka MJ, Nicholson KG, Kent J et al. . Prophylactic intranasal alpha 2 interferon and viral exacerbations of chronic respiratory disease. Thorax 1991; 46:706–11.
    1. El-Sahly HM, Atmar RL, Glezen WP, Greenberg SB. Spectrum of clinical illness in hospitalized patients with “common cold” virus infections. Clin Infect Dis 2000; 31:96–100.
    1. Hamm RM, Hicks RJ, Bemben DA. Antibiotics and respiratory infections: are patients more satisfied when expectations are met?J Fam Pract 1996; 43:56–62.
    1. Howick J, Cals JW, Jones C et al. . Current and future use of point-of-care tests in primary care: an international survey in Australia, Belgium, The Netherlands, the UK and the USA. BMJ Open 2014; 4:e005611.

Source: PubMed

Sponzoři a spolupracovníci

Zdravotní podmínky

Drogové intervence

3
Předplatit